Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall 4EF
Purpose: Hepatic dysfunction is common in patients with cardiomyopathy being evaluated for heart transplant (HT). ISHLT guidelines highlight the need for liver evaluation in patients with restrictive cardiomyopathy, congenital heart disease or chronic viral hepatitis, but do not specify a method for evaluation. We sought to examine outcomes of patients at our center undergoing liver evaluation prior to HT.
Methods: The study cohort included adult HT recipients at Cedars-Sinai Medical Center between 2010 and 2016 who underwent liver evaluation by ultrasound and/or computed tomography (n=293). Patients with abnormal imaging underwent transjugular liver biopsy (LB) when clinically indicated. Fibrosis was scored by a liver pathologist as: 0 none, 1 mild, 2 moderate and 3-4 severe. Survival was analyzed for patients undergoing HT alone (n=288) using the Kaplan-Meier method and the Cox model.
Results: Liver parenchyma was abnormal in 86 patients (29%). Imaging revealed heterogeneous parenchyma in 62 (72%) and nodular parenchyma in 24 (28%). Of these, 47 patients had LB pathology available. Pathology revealed mild fibrosis in 19, moderate fibrosis in 11 and severe fibrosis in 9. Nodular regenerative hyperplasia (NRH) was present in 19. Post-HT survival at 3 years did not differ by imaging findings (p=0.90) or by the need for LB (p=0.38). However, increasing fibrosis score predicted an increased mortality (hazard ratio 2.6, p=0.04). There was a trend towards increased mortality in patients with severe fibrosis (hazard ratio 6.3, p=0.07). Post-HT survival was not different in patients NRH.
Conclusion: Although abnormal liver imaging was common in patients being evaluated for HT, severe fibrosis was uncommon. Thus, liver imaging is not sufficient to determine the need for heart-liver transplant. Because patients with severe fibrosis experienced increased mortality, LB is an important part of the pre-HT liver evaluation. A larger study cohort is needed to confirm these findings.
|Normal (n=207)||Heterogenous (n=62)||Nodular (n=24)|
CITATION INFORMATION: Patel J., Kittleson M., Kransdorf E., Levine R., Dimbil S., Geft D., Chang D., Czer L., Kobashigawa J. Liver Biopsy Fibrosis Not Liver Imaging Predicts Survival after Heart Transplant Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:Patel J, Kittleson M, Kransdorf E, Levine R, Dimbil S, Geft D, Chang D, Czer L, Kobashigawa J. Liver Biopsy Fibrosis Not Liver Imaging Predicts Survival after Heart Transplant [abstract]. https://atcmeetingabstracts.com/abstract/liver-biopsy-fibrosis-not-liver-imaging-predicts-survival-after-heart-transplant/. Accessed November 25, 2020.
« Back to 2018 American Transplant Congress